Streetbeat News

Analyst Ratings

AVNT

Oppenheimer analyst Kristen Owen has maintained an 'Outperform' rating on Avient (NYSE:AVNT) and raised the price target from $53 to $58.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 3:25 pm

DECK

TD Cowen analyst John Kernan maintains a Buy rating on Deckers Outdoor (NYSE:DECK) and raises the price target from $176 to $178.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 3:22 pm

JACK

Loop Capital has maintained a Buy rating on Jack In The Box but lowered its price target from $87 to $70.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 3:21 pm

BRDG

TD Cowen analyst Bill Kirk has downgraded Bridge Investment Group (NYSE:BRDG) from Buy to Hold, indicating a more cautious outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 3:18 pm

SKX

TD Cowen analyst John Kernan maintains a Buy rating on Skechers USA (NYSE:SKX) but lowers the price target from $78 to $76.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 3:16 pm

MPW

Deep-pocketed investors are showing significant interest in Medical Properties Trust (NYSE:MPW), with a notable increase in options activity. The sentiment is mixed, with 58% bullish and 41% bearish. The stock is currently down 5.47% at $4.49, and RSI suggests it may be oversold.

Portfolio Pulse from Benzinga Insights

October 14, 2024 | 3:15 pm

LBPH

Cantor Fitzgerald has downgraded Longboard Pharmaceuticals from Overweight to Neutral, indicating a change in the analyst's outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 3:14 pm

UPST

Upstart Holdings shares surged after Wedbush upgraded the stock from Underperform to Neutral and increased its price target from $10 to $45.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 3:11 pm

TXT

JP Morgan analyst Seth Seifman maintains a Neutral rating on Textron (NYSE:TXT) and lowers the price target from $100 to $95.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 3:11 pm

CSTL

BTIG analyst Sung Ji Nam has maintained a Buy rating on Castle Biosciences and raised the price target from $35 to $40.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 3:10 pm